These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 16794579)

  • 1. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation.
    Anido J; Scaltriti M; Bech Serra JJ; Santiago Josefat B; Todo FR; Baselga J; Arribas J
    EMBO J; 2006 Jul; 25(13):3234-44. PubMed ID: 16794579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HER2/neu in tumor progression and therapy.
    Ménard S; Casalini P; Campiglio M; Pupa SM; Tagliabue E
    Cell Mol Life Sci; 2004 Dec; 61(23):2965-78. PubMed ID: 15583858
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Extra-virgin olive oil polyphenols inhibit HER2 (erbB-2)-induced malignant transformation in human breast epithelial cells: relationship between the chemical structures of extra-virgin olive oil secoiridoids and lignans and their inhibitory activities on the tyrosine kinase activity of HER2.
    Menendez JA; Vazquez-Martin A; Oliveras-Ferraros C; Garcia-Villalba R; Carrasco-Pancorbo A; Fernandez-Gutierrez A; Segura-Carretero A
    Int J Oncol; 2009 Jan; 34(1):43-51. PubMed ID: 19082476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression of HER2 and estrogen receptor alpha depends upon nuclear localization of Y-box binding protein-1 in human breast cancers.
    Fujii T; Kawahara A; Basaki Y; Hattori S; Nakashima K; Nakano K; Shirouzu K; Kohno K; Yanagawa T; Yamana H; Nishio K; Ono M; Kuwano M; Kage M
    Cancer Res; 2008 Mar; 68(5):1504-12. PubMed ID: 18316615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GRB-7 facilitates HER-2/Neu-mediated signal transduction and tumor formation.
    Bai T; Luoh SW
    Carcinogenesis; 2008 Mar; 29(3):473-9. PubMed ID: 17916906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
    Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
    Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dominant-negative N-terminal fragment of HER2 frequently expressed in breast cancers.
    Morancho B; Parra-Palau JL; Ibrahim YH; Bernadó Morales C; Peg V; Bech-Serra JJ; Pandiella A; Canals F; Baselga J; Rubio I; Arribas J
    Oncogene; 2013 Mar; 32(11):1452-9. PubMed ID: 22641219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vasoactive intestinal peptide (VIP) induces transactivation of EGFR and HER2 in human breast cancer cells.
    Valdehita A; Bajo AM; Schally AV; Varga JL; Carmena MJ; Prieto JC
    Mol Cell Endocrinol; 2009 Apr; 302(1):41-8. PubMed ID: 19101605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human epidermal growth factor receptor 2 regulates angiopoietin-2 expression in breast cancer via AKT and mitogen-activated protein kinase pathways.
    Niu G; Carter WB
    Cancer Res; 2007 Feb; 67(4):1487-93. PubMed ID: 17308086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transactivation of HER2 by vasoactive intestinal peptide in experimental prostate cancer: Antagonistic action of an analog of growth-hormone-releasing hormone.
    Sotomayor S; Carmena MJ; Schally AV; Varga JL; Sánchez-Chapado M; Prieto JC; Bajo AM
    Int J Oncol; 2007 Nov; 31(5):1223-30. PubMed ID: 17912451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activated Akt signaling pathway in invasive ductal carcinoma of the breast: correlation with HER2 overexpression.
    Park SS; Kim SW
    Oncol Rep; 2007 Jul; 18(1):139-43. PubMed ID: 17549359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p95HER2 and breast cancer.
    Arribas J; Baselga J; Pedersen K; Parra-Palau JL
    Cancer Res; 2011 Mar; 71(5):1515-9. PubMed ID: 21343397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The N-terminal domain of EBNA1 acts as a suppressor of the HER2/neu oncogene.
    Liu JY; Chuang TC; Way TD; Tsai TC; Hu CL; Liu GY; Wang SS; Chung JG; Kao MC
    Cancer Lett; 2009 Jan; 273(2):273-80. PubMed ID: 18805633
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted delivery of tumor antigens to activated dendritic cells via CD11c molecules induces potent antitumor immunity in mice.
    Wei H; Wang S; Zhang D; Hou S; Qian W; Li B; Guo H; Kou G; He J; Wang H; Guo Y
    Clin Cancer Res; 2009 Jul; 15(14):4612-21. PubMed ID: 19584156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Geldanamycin destabilizes HER2 tyrosine kinase and suppresses Wnt/beta-catenin signaling in HER2 overexpressing human breast cancer cells.
    Wang K; Ma Q; Ren Y; He J; Zhang Y; Zhang Y; Chen W
    Oncol Rep; 2007 Jan; 17(1):89-96. PubMed ID: 17143483
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel proximity assay for the detection of proteins and protein complexes: quantitation of HER1 and HER2 total protein expression and homodimerization in formalin-fixed, paraffin-embedded cell lines and breast cancer tissue.
    Shi Y; Huang W; Tan Y; Jin X; Dua R; Penuel E; Mukherjee A; Sperinde J; Pannu H; Chenna A; DeFazio-Eli L; Pidaparthi S; Badal Y; Wallweber G; Chen L; Williams S; Tahir H; Larson J; Goodman L; Whitcomb J; Petropoulos C; Winslow J
    Diagn Mol Pathol; 2009 Mar; 18(1):11-21. PubMed ID: 19214113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy.
    Milanezi F; Carvalho S; Schmitt FC
    Expert Rev Mol Diagn; 2008 Jul; 8(4):417-34. PubMed ID: 18598224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protein array technology to detect HER2 (erbB-2)-induced 'cytokine signature' in breast cancer.
    Vazquez-Martin A; Colomer R; Menendez JA
    Eur J Cancer; 2007 May; 43(7):1117-24. PubMed ID: 17379503
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioactive synthetic peptide of NDF/heregulin.
    Kita Y; Mayer J; Zamborelli T; Hara S; Rohde M; Watson E; Koski R; Ratzkin B; Nicolson M
    Biochem Biophys Res Commun; 1995 May; 210(2):441-51. PubMed ID: 7755620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. VERO stable cell lines expressing full-length human epidermal growth factor receptors 2 and 3: platforms for subtractive phage display.
    Hedayatizadeh-Omran A; Valadan R; Rafiei A; Tehrani M; Alizadeh-Navaei R
    DNA Cell Biol; 2015 Sep; 34(9):573-8. PubMed ID: 26121156
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.